Applied Therapeutics Inc. (APLT) shares plummeted over 75% in the pre-market session on Friday, following the U.S. Food and Drug Administration's (FDA) decision to reject the company's New Drug Application (NDA) for govorestat in treating classic galactosemia, a rare genetic metabolic disorder.
The FDA issued a Complete Response Letter (CRL) to APLT, stating that the clinical application for govorestat had deficiencies and failed to meet the necessary requirements for approval. This unexpected setback has led analysts to significantly downgrade their outlook on the biopharmaceutical company.
RBC Capital Markets downgraded APLT from "Outperform" to "Sector Perform" and slashed its price target from $12 to $4, citing increased risks and uncertainties around govorestat's future prospects after the FDA rejection. Meanwhile, APLT plans to request a meeting with the FDA to discuss the requirements for a potential NDA resubmission or appeal. The company is also developing govorestat for sorbitol dehydrogenase deficiency and intends to file an NDA for that indication in the first quarter of 2025.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。